Beijing biologics maker known for recombinant nerve growth factor drugs treating neurological injuries and neuropathy.
Beijing biologics maker known for recombinant nerve growth factor drugs treating neurological injuries and neuropathy.
In one line: A small, single-product Chinese biologics maker.
Moat: narrow (IP / patents, regulatory licence). One of few approved nerve-growth-factor biologics in China, protecting near-term market share.
Headquarters: Beijing, China · Employees: 491
Size Staidson (Beijing) Biopharmaceuticals (300204.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.26B, the 1771st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.92 on 18 Nov 2026.
Performance Over six months the shares fell 41.3%, against -9.6% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 23.5% over the last twelve months (peer median +3.1%); the operating margin is -51.2% (peer median 0.8%).
Valuation It trades at 522.3× forward earnings against a peer median of 20.0× (most expensive of 11).
Capital Return on invested capital runs 16.3 points below its cost of capital (10.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥187M | CN¥219M | CN¥323M | CN¥360M | CN¥542M |
| Revenue growth | — | -32% | -10% | -34% | — |
| Gross profit | CN¥150M | CN¥160M | CN¥246M | CN¥275M | CN¥418M |
| EBITDA | n/a | -CN¥58.9M | -CN¥21.0M | -CN¥340M | -CN¥224M |
| Net income | -CN¥99.5M | -CN¥77.8M | -CN¥145M | -CN¥399M | -CN¥197M |
| Free cash flow | -CN¥187M | -CN¥202M | -CN¥86.7M | -CN¥260M | -CN¥226M |
| Capital expenditure | CN¥113M | CN¥76.6M | CN¥23.5M | CN¥32.2M | CN¥56.5M |
| Total debt | CN¥760,797 | CN¥301M | CN¥42.5M | CN¥41.0M | CN¥29.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300204.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.4% | -4.8% | 3rd lowest of 20 |
| 6-month return | -41.3% | -9.6% | 3rd lowest of 20 |
| Distance from 52-week high | -60.6% | -37.1% | 4th lowest of 20 |
| Revenue growth (TTM) | -23.5% | +3.1% | 3rd lowest of 16 |
| Operating margin | -51.2% | 0.8% | 5th lowest of 16 |
| Forward P/E | 522.3× | 20.0× | most expensive of 11 |
| ROIC minus cost of capital | -16.3 pp | -4.8 pp | 4th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |